Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
But questions remain around bentracimab’s data package.